• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Fibrocell, Castle Creek Enter Collaboration contractpharma
    April 16, 2019
    To develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)...
  • Fibrocell Announces FDA Fast Track Designation of FCX-013 americanpharmaceuticalreview
    September 06, 2018
    Fibrocell Science announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma, a chronic, debilitating genet
  • Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market firstwordpharma
    May 30, 2018
    EXTON, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service